CORAL GABLES, Fla., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and ...

Seizures can affect your daily life and well-being. Certain medicines can help lower the risk of having seizures, which can help manage your condition. Fycompa is a medicine used to manage ...

Fycompa bottle Safety data for Fycompa was consistent with the safety profile in adult populations without the need for weight-based dosing. The Food and Drug Administration has expanded the use of ...

CORAL GABLES, Fla., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and ...

The proposed pediatric indications are based on a 2018 Draft Guidance that supports extrapolating efficacy data of approved drugs to treat POS in adults to pediatric patients aged ≥4 years. Fycompa, ...

With Eisai on the verge of scoring a potential approval for its Biogen-partnered Alzheimer’s disease drug lecanemab, the Japanese pharma is thinking big. Monday, Eisai inked a deal to unload one of ...

Clinigen has expanded its agreement with Eisai to exclusively market Halaven, Fycompa and Lenvima in 10 African countries. The new deal was built on Clinigen obtaining South African marketing rights ...

Patients with a particular form of epilepsy in the UK can now access Eisai’s Fycompa to reduce serious seizures after regulators expanded the scope of the anti-convulsant’s reach last month. Patients ...

Late-stage data unveiled at the International Epilepsy Congress in Istanbul have backed the efficacy of Eisai’s Fycompa in reducing the frequency of seizures in patients with primary generalised tonic ...

The US Food and Drug Administration (FDA) has approved perampanel oral suspension (Fycompa, Eisai Inc.) as adjunctive therapy for treatment of partial-onset seizures with or without secondarily ...

Fycompa approved for partial onset seizures The FDA has approved Fycompa tablets to treat partial onset seizures in individuals aged 12 years and older who have epilepsy, HealthDay News — The FDA has ...